AL001, developed by Alector Inc., targets C9orf72-associated ALS, a genetic form of the disease with significant unmet medical need. The ALS market is projected to grow due to increasing prevalence and awareness, with current therapies offering limited efficacy. Alector's focus on a specific genetic mutation positions it uniquely against competitors, particularly in a landscape dominated by symptomatic treatments. The termination of this trial suggests a strategic pivot, potentially indicating challenges in meeting inclusion criteria or efficacy expectations, which may affect investor confidence and future funding.